Nicergoline

Nicergoline
Clinical data
Trade names	Sermion
Other names	[(8β)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyridine-3-carboxylate
AHFS/Drugs.com	International Drug Names
Pregnancy; category	Not recommended;
Routes of; administration	By mouth, intramuscular, intravenous
ATC code	C04AE02 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Pharmacokinetic data
Bioavailability	<5%
Protein binding	>90%
Metabolism	Extensive First-pass metabolism
Elimination half-life	13–20 hours
Identifiers
	IUPAC name [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate;
CAS Number	27848-84-6 ;
PubChem CID	34040;
DrugBank	DB00699 ;
ChemSpider	31373 ;
UNII	JCV8365FWN;
KEGG	D01290 ;
ChEMBL	ChEMBL1372950 ;
CompTox Dashboard (EPA)	DTXSID7045607 ;
ECHA InfoCard	100.044.252
Chemical and physical data
Formula	C24H26BrN3O3
Molar mass	484.394 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Brc1cc(cnc1)C(=O)OC[C@@H]3C[C@]4(OC)c5cccc2c5c(cn2C)C[C@H]4N(C3)C;
	InChI InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1 ; Key:YSEXMKHXIOCEJA-FVFQAYNVSA-N ;
	(what is this?) (verify)

Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other ergolines, such as ergotamine, nicergoline is not associated with cardiac fibrosis.^[2]

It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascular migraines, and retinopathy.

Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.^[3]

^ "List of nationally authorised medicinal products" (PDF). Archived (PDF) from the original on 11 July 2024. Retrieved 11 July 2024.
^ Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths". Pharmacological Reports. 67 (2): 360–363. doi:10.1016/j.pharep.2014.10.010. PMID 25712664. S2CID 22768662.
^ Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". The Cochrane Database of Systematic Reviews. 2001 (4): CD003159. doi:10.1002/14651858.CD003159. PMC 7025776. PMID 11687175.

[1] "List of nationally authorised medicinal products" (PDF). Archived (PDF) from the original on 11 July 2024. Retrieved 11 July 2024.

[ncbi.nlm.nih.gov-2] Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths". Pharmacological Reports. 67 (2): 360–363. doi:10.1016/j.pharep.2014.10.010. PMID 25712664. S2CID 22768662.

[3] Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". The Cochrane Database of Systematic Reviews. 2001 (4): CD003159. doi:10.1002/14651858.CD003159. PMC 7025776. PMID 11687175.

[1]

[2]

[3]